

Special Issue

Advancements in Cellular Immunotherapies in the Immune Checkpoint Inhibitor Era for Cancer Treatment

Message from the Guest Editors

The landscape of cancer treatment has undergone a remarkable transformation with the advent of immune checkpoint inhibitors (ICIs). These groundbreaking therapies have ushered in a new era in the fight against cancer by unleashing the power of the immune system to target and destroy malignant cells. Concurrently, cellular immunotherapies have emerged as a promising treatment frontier, offering personalized and precise approaches to combat this complex disease. Cell-mediated immunity can eliminate cancer cells and provide durable remissions. This Special Issue, entitled "Advancements in Cellular Immunotherapies in the Immune Checkpoint Inhibitor Era for Cancer Treatment," aims to provide a comprehensive overview of the latest developments in this dynamic field, including dendritic cell-based vaccines, whole-tumor-cell vaccines, and adoptive cell (T-cell, NK cell, or CAR-T cell) transfer.

Guest Editors

Dr. Andrés Tittarelli

Programa Institucional de Fomento a la Investigación, Desarrollo e Innovación, Universidad Tecnológica Metropolitana, Santiago 8940577, Chile

Dr. Flavio Salazar-Onfray

1. Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago 8380453, Chile
2. Millennium Institute on Immunology and Immunotherapy, Santiago 8380453, Chile
3. Department of Medicine Solna, Karolinska Institute, 17176 Stockholm, Sweden

Deadline for manuscript submissions

closed (30 June 2025)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/186922

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/

[cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).